PharmaceuticalIndustry News

PharmaceuticalIndustry News From AOL News

Opinion: Will Health Reform Save Lives?

(March 4) -- In the course of the heated debate over "ObamaCare" legislation, Washington Post blogger Ezra Klein accused Sen. Joe Lieberman of being "willing to cause the deaths of hundreds of thousands of people" after Lieberman threatened to filibuster the bill. Klein's claim came from a study by the Urban Institute,...

PharmaceuticalIndustry News From AOL

AOL MONEY & FINANCE

House OKs FDA bill to increase inspections, fees

WASHINGTON -The Food and Drug Administration would have more power to catch tainted pharmaceuticals manufactured overseas before they enter the U.S. market under legislation passed Wednesday by House lawmakers.

THE HUFFINGTON POST

Dave Murphy: 20 Years of GMO Policy That Keeps Americans in the Dark About Their Food

Popular resistance is boiling over on the GMO labeling issue, as the New York Times reported last week in a front-page story.

THE HUFFINGTON POST

Trade Deals For Cheap Drugs In Developing Nations Stalled By U.S.

A change of heart from the Obama administration may pave the way to a groundbreaking global deal to provide lifesaving medications to developing nations.

THE HUFFINGTON POST - BUSINESS

FDA Shoots Down Drug For Fatal Rare Disease

U.S. drug reviewers on Tuesday recommended rejecting a Pfizer Inc drug because the data did not prove it worked well in treating a rare neurodegenerative disease.

THE HUFFINGTON POST - BUSINESS

An Idea To Fix Killer Costs Of Lifesaving Drugs

Sen. Bernie Sanders (I-Vt.) is promoting a new plan to encourage the development of better, cheaper prescription drugs: an innovation fund rewarding companies for inventing important new HIV and AIDS medications.

PharmaceuticalIndustry News From the Web

05/31/12 Biovest Interviewed by OneMedRadio; Discusses Key... Source: Infospace Inc TAMPA, Fla. & MINNEAPOLIS--( BUSINESS WIRE )--Biovest International, Inc. (OTCQB: "BVTI"), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: "ABPI"), today announced that Brett Johnson, President and Executive Editor of OneMedPlace interviewed Biovest's President and CEO, Samuel S. Duffey, and its Senior Vice President, Product Development & Regulatory Affairs, Carlos F. Santos, Ph.D. In the webcast audio interview on OneMedRadio, Biovest discussed its global regulatory strategy for BiovaxIDÂ®, Biovest's personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, including plans to file applications in the EU and Canada seeking approvals.
05/31/12 Antibiotic Resistance Program Launched in Europe Source: BioPharm International The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the launch of a â¬223.7-million ($276.5 million) program to tackle antimicrobial resistance and speed up the development of new antibiotics.
05/31/12 WestPark Capital, Inc. Engaged By Alliqua, Inc. Source: StockHouse LOS ANGELES, May 31, 2012 /PRNewswire/ --WestPark Capital, Inc., a Los Angeles based investment banking company, today announced it has signed a non-exclusive engagement agreement with Alliqua, Inc.
05/31/12 Class I Recall Issued For Potentially Contaminated... Source: NewsInferno A Class I recall has been issued for potentially contaminated ultrasound gel, the U.S. Food & Drug Administration (FDA) just announced.
05/31/12 Medivation (MDVN) Target of Negative TheStreetSweeper... Source: StreetInsider.com Medivation, Inc. (Nasdaq: MDVN ) is seeing mild pressure Thursday afternoon following a negative report at TheStreetSweeper.org. The report said, ".... the stock trades at lofty levels that fail to properly reflect the following: rights to only a portion of future drug sales and initial access to only a limited section of the market; fierce competition from a similar drug and documented progress toward a superior version of its own therapy; inexperience in commercial operations and dependence on a marketing partner where sales reps have long complained of toxic working conditions; and prior clinical results that sparked false hopes for an earlier drug that ultimately failed, scaring off an industry giant and staining its record with a potential source of ongoing doubt."